Professor Wing Cheong Chow: Controversies, Risk-Stratified Pathways, and Localization of Breast Cancer Screening Strategies in Asia | 2026 Lingnan Breast Cancer Academic Forum

Professor Wing Cheong Chow: Controversies, Risk-Stratified Pathways, and Localization of Breast Cancer Screening Strategies in Asia | 2026 Lingnan Breast Cancer Academic Forum

Breast cancer is one of the most common malignancies among women worldwide. Optimizing screening strategies is essential to improving early detection and reducing mortality. The 2026 Lingnan Breast Cancer Academic Forum was recently held in Guangzhou. At the meeting, Professor Wing Cheong Chow, Medical Director of the Comprehensive Breast Care Centre at Hong Kong Yan Hong Medical Centre, delivered a presentation entitled “Controversies of Breast Cancer Screening Strategies in Asia,” examining the challenges that breast characteristics among Asian women pose for mammography and outlining potential screening approaches. Following the presentation, Oncology Frontier invited Professor Chow to discuss current controversies surrounding the choice of breast cancer screening modalities in Asia, as well as how to balance the risks of overdiagnosis and missed diagnoses.
CSCO 2026 | Professor Qiang Wei: Real-World Evidence Further Validates the Clinical Benefits of Enzalutamide-Based Combination Therapy in Older, Frail, and Comorbidity-Burdened Patients With mCSPC

CSCO 2026 | Professor Qiang Wei: Real-World Evidence Further Validates the Clinical Benefits of Enzalutamide-Based Combination Therapy in Older, Frail, and Comorbidity-Burdened Patients With mCSPC

The 2026 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, China. At the meeting, Professor Qiang Wei of the Department of Urology at West China Hospital, Sichuan University, presented a poster based on real-world data from the US Veterans Health Administration (VHA), focusing on patients with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) who were older, frail, or had a high burden of comorbidities.
A New Beginning Through Comprehensive Prostate Cancer Care | Professor Benkang Shi: ADT Continues to Evolve—Precision Castration and Combination Therapy Transforming Prostate Cancer Management Across the Disease Continuum

A New Beginning Through Comprehensive Prostate Cancer Care | Professor Benkang Shi: ADT Continues to Evolve—Precision Castration and Combination Therapy Transforming Prostate Cancer Management Across the Disease Continuum

Prostate cancer is one of the most common malignancies among men in China, and its development and progression are closely associated with androgens. Consequently, androgen deprivation therapy (ADT) remains an indispensable cornerstone throughout the prostate cancer disease continuum, from localized disease and metastatic hormone-sensitive prostate cancer to castration-resistant prostate cancer.
17th Yanzhao Breast Cancer Forum | Professor Hong Bu: Digital and Intelligent Pathology Is Reshaping Diagnosis, With Human–AI Collaboration as the Foundation of Precision Medicine

17th Yanzhao Breast Cancer Forum | Professor Hong Bu: Digital and Intelligent Pathology Is Reshaping Diagnosis, With Human–AI Collaboration as the Foundation of Precision Medicine

Pathological diagnosis is the cornerstone of precision breast cancer care. In recent years, rapid advances in digital scanning, artificial intelligence (AI), and multimodal integration have driven a profound transformation in breast pathology, moving it beyond traditional morphological diagnosis toward a digital and intelligent paradigm. These developments offer new tools and evidence to support precise breast cancer classification, treatment response prediction, and individualized therapy. The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. During the meeting, Oncology Frontier invited Professor Hong Bu of West China Hospital, Sichuan University, to discuss the development of digital and intelligent breast pathology, drawing on his presentation entitled “The Development of Digital and Intelligent Breast Pathology.” He shared his insights into the key stages of development, the clinical implementation of AI and human–AI collaboration, the digital transformation of pathology, and its clinical value.
17th Yanzhao Breast Cancer Forum | Professor Yunjiang Liu: Advancing Standardized Breast Surgery and Expanding Access to Oncoplastic and Reconstructive Techniques at the Grassroots Level

17th Yanzhao Breast Cancer Forum | Professor Yunjiang Liu: Advancing Standardized Breast Surgery and Expanding Access to Oncoplastic and Reconstructive Techniques at the Grassroots Level

The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. Jointly organized by the Beijing Breast Disease Prevention and Treatment Society and the Hebei Clinical Oncology Society, and hosted by the Hebei Provincial Breast Disease Diagnosis and Treatment Center and the Breast Center of the Fourth Hospital of Hebei Medical University, the forum adhered to its guiding principles of “pragmatism, standardization, and development.” It brought together leading breast cancer experts from across China for in-depth discussions on key topics, including surgery, systemic therapy, pathological diagnosis, and multidisciplinary collaboration. During the meeting, Oncology Frontier invited Professor Yunjiang Liu of the Fourth Hospital of Hebei Medical University for an exclusive interview. He shared his insights into breast surgery practices in Hebei Province, the design of training programs in oncoplastic and reconstructive techniques, and strategies for extending these techniques to primary-level hospitals.
17th Yanzhao Breast Cancer Forum | Professor Zhenchuan Song: Leading Experts Share Cutting-Edge Insights, While MDT Advances Comprehensive Care and Standardization at the Grassroots Level

17th Yanzhao Breast Cancer Forum | Professor Zhenchuan Song: Leading Experts Share Cutting-Edge Insights, While MDT Advances Comprehensive Care and Standardization at the Grassroots Level

The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. Continuing the forum's longstanding academic tradition, this year's meeting featured a series of lectures by leading experts from across China, who engaged in in-depth discussions on key topics in breast cancer diagnosis and treatment, as well as specialty development. The multidisciplinary team (MDT) case discussion session was another major component of the forum, focusing on the central role of MDT in the comprehensive management of breast cancer and examining the current status and challenges of extending MDT services to primary-level hospitals. During the meeting, Oncology Frontier invited Professor Zhenchuan Song of the Fourth Hospital of Hebei Medical University to share his insights into the academic highlights of the expert lecture series and specialty development, the core value of MDT in comprehensive patient management, and the challenges and strategies involved in promoting MDT at the grassroots level.
2026 CSCO China–International Dialogue | Professor Kai-Keen Shiu (蕭啓堅教授) analyzes breakthrough strategies for immunotherapy in MSS/pMMR colorectal cancer

2026 CSCO China–International Dialogue | Professor Kai-Keen Shiu (蕭啓堅教授) analyzes breakthrough strategies for immunotherapy in MSS/pMMR colorectal cancer

The 2026 CSCO Annual Meeting was held in Jinan from September 16 to 19, bringing together scholars from around the world in its international sessions. Prof. Kai-Keen Shiu of the UCL Cancer Institute delivered a special lecture titled “Immuno-resistant CRC treatment” at the conference. Oncology Frontier–UroStream conducted an exclusive interview with him on site, systematically covering the core mechanisms of immunotherapy-resistant colorectal cancer (CRC), breakthrough strategies for microsatellite-stable (MSS) tumors, and practical experience in biomarker testing and patient management. He also shared his assessment of China’s progress in precision therapy and immunotherapy, as well as his expectations for future China–international collaboration, providing valuable reference for CRC treatment in China.
17th Yanzhao Breast Cancer Forum | Professor Shusen Wang: From MECCA to SYSUCC-020—Endocrine Therapy Plus Metronomic Chemotherapy Opens a New Chapter in HR-Positive/HER2-Negative Breast Cancer Treatment

17th Yanzhao Breast Cancer Forum | Professor Shusen Wang: From MECCA to SYSUCC-020—Endocrine Therapy Plus Metronomic Chemotherapy Opens a New Chapter in HR-Positive/HER2-Negative Breast Cancer Treatment

Hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer is the most common molecular subtype of breast cancer. For decades, the combination of endocrine therapy and chemotherapy was considered a therapeutic “forbidden zone” because of its theoretical basis and early clinical evidence. With the emergence of novel endocrine agents, chemotherapeutic drugs, antibody–drug conjugates (ADCs), and evolving treatment strategies, this traditional view is gradually being challenged. In recent years, metronomic chemotherapy has emerged as a promising approach to combining chemotherapy with endocrine therapy because of its distinctive antiangiogenic and immunomodulatory mechanisms and favorable safety profile. The MECCA and SYSUCC-020 studies have provided important evidence supporting this strategy in the first-line setting and among patients previously treated with CDK4/6 inhibitors, respectively.
CSCO DocX TALK | Upholding Core Principles and Driving Innovation: Professor Heinz-Josef Lenz and HUTCHMED Discuss the Globalization of China’s Innovative Oncology Drugs

CSCO DocX TALK | Upholding Core Principles and Driving Innovation: Professor Heinz-Josef Lenz and HUTCHMED Discuss the Globalization of China’s Innovative Oncology Drugs

The 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting showcased cutting-edge advances in oncology worldwide, with China's innovative drug development attracting particular attention. China has become an increasingly important force in global cancer research and treatment. During the meeting, Oncology Frontier invited Professor Heinz-Josef Lenz of USC Norris Comprehensive Cancer Center and Mr. George Yuan, Executive Vice President of HUTCHMED, to engage in an in-depth dialogue under the theme “Upholding Core Principles and Driving Innovation: Moving Forward Together.”